Medicare Plan to Verify Negotiated Drug Prices Spurs Unease (1)

The Medicare system proposed by the Biden administration to verify negotiated drug prices reach eligible individuals is generating concerns about compliance and operational challenges for manufacturers and dispensing entities.

The Centers for Medicare & Medicaid Services continues to swiftly roll out its drug price negotiation program after publishing a draft guidance earlier this month for the next cycle of its price-setting scheme. The plan, created under the Inflation Reduction Act, is expected to lower the costs of 10 Medicare Part D drugs as of 2026 and another 15 drugs in 2027.

The guidance introduced new details on the implementation of ...